$458 Million is the total value of 5AM Venture Management, LLC's 19 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 11.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PEAR THERAPEUTICS INC | $94,090,000 | -18.5% | 18,631,771 | 0.0% | 20.55% | -5.2% | ||
| New | CINCOR PHARMA INC | $76,082,000 | – | 4,337,646 | +100.0% | 16.62% | – | |
| ENTRADA THERAPEUTICS INC | $41,395,000 | -45.2% | 4,408,379 | 0.0% | 9.04% | -36.2% | ||
| VOR | VOR BIOPHARMA INC | $38,425,000 | -48.0% | 6,361,723 | 0.0% | 8.39% | -39.5% | |
| Sell | RALLYBIO CORP | $27,785,000 | -30.5% | 3,980,724 | -5.0% | 6.07% | -19.1% | |
| ARVN | ARVINAS INC | $26,920,000 | -18.1% | 400,000 | 0.0% | 5.88% | -4.7% | |
| SCPH | SCPHARMACEUTICALS INC | $21,763,000 | +13.1% | 3,831,474 | 0.0% | 4.75% | +31.7% | |
| AKUS | AKOUOS INC | $19,645,000 | -44.1% | 4,135,784 | 0.0% | 4.29% | -35.0% | |
| CRNX | CRINETICS PHARMACEUTICALS IN | $18,927,000 | -22.7% | 862,286 | 0.0% | 4.13% | -10.1% | |
| IMPL | IMPEL NEUROPHARMA INC | $18,376,000 | -26.2% | 2,884,791 | 0.0% | 4.01% | -14.1% | |
| ISEE | Buy | IVERIC BIO INC | $17,299,000 | +60.8% | 1,027,874 | +59.8% | 3.78% | +87.2% |
| IDYA | IDEAYA BIOSCIENCES INC | $15,644,000 | -52.7% | 1,398,066 | 0.0% | 3.42% | -44.9% | |
| FIXX | HOMOLOGY MEDICINES INC | $13,789,000 | -16.5% | 4,535,919 | 0.0% | 3.01% | -2.8% | |
| RNA | AVIDITY BIOSCIENCES INC | $7,214,000 | -22.3% | 390,555 | 0.0% | 1.58% | -9.5% | |
| JANX | JANUX THERAPEUTICS INC | $6,399,000 | -27.3% | 446,266 | 0.0% | 1.40% | -15.4% | |
| COGT | New | COGENT BIOSCIENCES INC | $5,328,000 | – | 711,412 | +100.0% | 1.16% | – |
| CABA | CABALETTA BIO INC | $4,190,000 | -46.4% | 2,064,263 | 0.0% | 0.92% | -37.7% | |
| FVAM | 5 01 ACQUISITION CORP | $3,596,000 | 0.0% | 365,126 | 0.0% | 0.78% | +16.3% | |
| CDTX | CIDARA THERAPEUTICS INC | $945,000 | -34.4% | 1,134,511 | 0.0% | 0.21% | -23.7% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| HOMOLOGY MEDICINES INC | 16 | Q3 2023 | 26.6% |
| ARVINAS INC | 16 | Q3 2023 | 14.3% |
| Crinetics Pharmaceuticals, Inc. | 16 | Q3 2023 | 12.8% |
| SCPHARMACEUTICALS INC | 16 | Q3 2023 | 7.5% |
| CIDARA THERAPEUTICS INC | 16 | Q3 2023 | 1.7% |
| IDEAYA BIOSCIENCES INC | 14 | Q1 2023 | 11.4% |
| VOR BIOPHARMA INC | 11 | Q3 2023 | 51.9% |
| CABALETTA BIO INC | 11 | Q2 2022 | 14.2% |
| AKOUOS INC | 10 | Q3 2022 | 27.7% |
| IMPEL PHARMACEUTICALS INC | 10 | Q3 2023 | 7.1% |
View 5AM Venture Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-03 |
| 13F-HR | 2021-11-15 |
View 5AM Venture Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.